Format

Send to

Choose Destination
BMJ. 2018 Feb 22;360:k587. doi: 10.1136/bmj.k587.

Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?

Author information

1
George Washington University School of Medicine, Washington, DC, USA.
2
Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA.
3
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
PMID:
29472192
DOI:
10.1136/bmj.k587
[Indexed for MEDLINE]

Conflict of interest statement

We thank Paul Sax, Ursula Theuretzbacher, Charles Natanson, and Irene Cortes Puch for their comments on previous drafts. Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following: ASK is a member of the Collaborative Research Programme in Biomedical Innovation Law at the University of Copenhagen (which is supported by grant NNF17SA027784 from the Novo Nordisk Foundation) and is funded by the Laura and John Arnold Foundation, with additional funding from the Harvard Program in Therapeutic Science and the Engelberg Foundation. He has received grants from the FDA Office of Generic Drugs and Division of Health Communication (2013-16). SRE is a member of the Antibacterial Resistance Leadership Group funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health; has served as a consultant for Roche, Pfizer, Takeda, Novartis, Merck, Achaogen, Cubist, GSK, Amgen, Boehringer-Ingelheim, Sunnovion, Taris, Alcon, Chelsea, Mannkind, QRx Pharma, Genentech, Auspex, Affymax, and FzioMed; and has received honorariums from the American Statistical Association, the Society for Clinical Trials, the FDA, the NIH, Osaka University, the National Cerebral and Cardiovascular Center of Japan, the Drug Information Association, the Huntington’s Study Group, the Muscle Study Group, the NJMS / Rutgers, the University of Rhode Island, Boston University, IMMPACT, PPRECISE, DeGruyter, Massachusetts General Hospital, and the City of Hope. JHP has served as a consultant for Abbvie, Cardeas, Cempra, Contrafect, Gilead, Johnson and Johnson, Lilly, MedImmune, Otsuka, and Roche and is an analysis adviser for The BMJ. All authors have contributed equally to the concepts, drafting, and review of this manuscript

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center